CAMBRIDGE, Mass.--(BUSINESS WIRE)--
BIND Therapeutics, Inc. (NASDAQ: BIND), a clinical-stage nanomedicine
platform company developing targeted and programmable therapeutics
called AccurinsTM, announced today that Scott Minick, BINDís
President and CEO, is scheduled to present at the Wedbush 2014 Life
Sciences Management Access Conference in New York on Wednesday, August
13, 2014 at 10:55 a.m. ET.
Interested parties may access a live webcast of the presentation by
visiting the BIND Therapeutics website at www.bindtherapeutics.com.
The webcasts will be archived on the BIND Therapeutics website following
the event for one week.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company
developing Accurins, its novel targeted therapeutics. BIND intends to
leverage its Medicinal Nanoengineeringģ platform to develop a pipeline
of Accurins, initially in oncology, as well as Accurins in collaboration
with biopharmaceutical companies. BINDís lead drug candidate, BIND-014,
is an Accurin that targets PSMA and contains docetaxel, a
clinically-validated and widely used cancer chemotherapy drug. BIND-014
is currently in Phase 2 clinical trials for the treatment of non-small
cell lung cancer and metastatic castrate-resistant prostate cancer.
BIND has announced ongoing collaborations with Pfizer Inc., AstraZeneca
AB and F. Hoffmann-La Roche Ltd. to develop Accurins based on their
proprietary therapeutic payloads and targeting ligands. BINDís platform
originated from the pioneering nanotechnology research at the
Massachusetts Institute of Technology and Brigham and Womenís
Hospital/Harvard Medical School of BINDís scientific founders Dr. Robert
Langer and Dr. Omid Farokhzad. For more information, please visit the
Company's web site at www.bindtherapeutics.com.
The Yates Network
Gina Nugent, 617-460-3579
Paul Cox, 212-362-1200
Source: BIND Therapeutics, Inc.